Role of Th17 cells and interleukin 17 in graft-versushost disease and graft-versusleukemia reactivity - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 292

[75] Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide
association study identifies IL23R as an inflammatory bowel disease gene. Science
2006;314:1461-3.
[76] Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray
of multiple sclerosis lesions yields new targets validated in autoimmune encephalomy-
elitis. Nat Med 2002;8:500-8.
[77] Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Collaborative Associa-
tion Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23
and NF-κB pathways. Nat Genet 2009;41:199-204.
[78] Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, et al.
Differential activity of IL-12 and IL-23 in mucosal and systemic innate pathology. Im-
munity 2006;25:309-18.
[79] Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al. Interleukin 23
drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006;203:
2473-83.
[80] Noguchi D, Wakita D, Tajima M, Ashino S, Iwakura Y, Zhang Y, et al. Blocking of IL-6 sig-
naling pathway prevents CD4 + T cell-mediated colitis in a T H 17-independent manner.
Int Immunol 2007;19:1431-40.
[81] Izcue A, Hue S, Buonocore S, Arancibia-Cárcamo CV, Ahern PP, Iwakura Y, et al. Inter-
leukin 23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity
2008;28:559-70.
[82] Thompson JS, Chu Y, Glass JF, Brown SA. Absence of IL-23p19 in donor allogeneic cells
reduces mortality from acute GVHD. Bone Marrow Transplant 2010;45:712-22.
[83] Pidala J, Perez L, Beato F, Anasetti C. Ustekinumab demonstrates activity in glucocorti-
coid-refractory acute GVHD. Bone Marrow Transplant 2012;47:747-8.
[84] Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4 + CD25 + T cell-mediat-
ed suppression by dendritic cells. Science 2003;299:1033-6.
[85] Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits
CD4+ CD25+ T cell regulatory functions. J Immunol 2007;178:271-9.
[86] Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, et al. Blockade of inter-
leukin 6 signaling augments regulatory T cell reconstitution and attenuates the severity
of graft versus host disease. Blood 2009;114:891-900.
[87] Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, et al. IL-6 blockade in-
hibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental
autoimmune encephalomyelitis. Proc Natl Acad U S A 2008;105:9041-6.
[88] Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, et al. Interleukin 6 modulates
graft versus host responses after experimental allogeneic bone marrow transplanta-
tion. Clin Cancer Res 2010;17:77-88.
[89] Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Rizzo JD, Saad A, et al. Tocilizumab for
the treatment of steroid refractory graft versus host disease. Biol Blood Marrow Trans-
plant 2011;17:1862-8.
[90] McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin
and lung fibrosis in murine sclerodermatous graft versus host disease: a model for hu-
man scleroderma. J Immunol 1999;163:5693-9.
[91] Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A, et al. TGF-beta in alloge-
neic stem cell transplantation: friend or foe? Blood 2005;106:2206-14.
[92] Giroux M, Delisle JS, Gauthier SD, Heinonen KM, Hinsinger J, Houde B, et al. SMAD3
prevent graft versus host disease by restraining T H 1 differentiation and granulocyte-
mediated tissue damage. Blood 2011;117:1734-44.
[93] Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17
lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ.
Immunity 2008;28:29-39.
[94] Brustle A, Heink S, Huber M, Rosenplanter C, Stadelmann C, Yu P, et al. The develop-
ment of inflammatory TH17 cells requires interferon-regulatory factor 4. Nat Immunol
2007;8:958-66.
[95] Zhang F, Meng G, Strober W. Interactions among the transcription factors Rinx1, RORγt
and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol
2008;9:1297-306.
[96] Yu Y, Wang D, Liu C, Kaosaard K, Semple K, Anasetti C, et al. Prevention of GVHD
while sparing GVL by targeting Th1 and Th17 transcription factor T-bet and RORγt in
mice. Blood 2011;118:5011-20.
[97] Sawa S, Cherrier M, Lochner M, Satoh-Takayama N, Fehling HJ, Langa F, et al. Lineage
relationship analysis of RORγt+ innate lymphoid cells. Science 2010;330:665-9.
[98] Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, Fuentes-
Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated
with reduced Th17 responses. J Exp Med 2007;204:3183-94.

295